This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ligand Pharmaceuticals, Inc.
Drug Names(s): MB07811
Description: MB07811 is an orally active prodrug of a novel thyroid hormone receptor (TRB) agonist designed to deliver the agonist to the site where cholesterol is produced, i.e. the liver, while reducing the exposure of the agonist to other tissues. MB07811 uses the Company's proprietary HepDirect prodrug technology to target a beta-subtype-selective TRB agonist to the liver to reduce serum cholesterol (LDL) and triglycerides (TGs).
Deal Structure: MB07811 was originally developed by Metabasis.
In October 2009, Ligand Pharmaceuticals and Metabasis Therapeutics announced they entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis. The acquisition was completed in January 2010.
Additional information available to subscribers only: